Description

Description

Diajard-M 12.5/500mg is a prescription medicine manufactured by Highnoon Laboratories, combining two active ingredients, Empagliflozin and Metformin, in a single tablet. This fixed-dose combination brings together two different mechanisms of blood sugar control, making it a convenient option for adults with type 2 diabetes mellitus whose condition requires more than one approach to management. Empagliflozin belongs to the sodium-glucose co-transporter 2 (SGLT2) inhibitor class, working by reducing glucose reabsorption in the kidneys and promoting its removal through urine. Metformin belongs to the biguanide class and works primarily by decreasing glucose production in the liver while improving how the body responds to insulin. Together, these two mechanisms complement one another to support more effective blood sugar control than either ingredient might achieve alone. Each pack of Diajard-M 12.5/500mg contains 14 tablets, produced under the quality standards upheld by Highnoon Laboratories.

Ingredients

Diajard-M 12.5/500mg contains two active ingredients: Empagliflozin at a strength of 12.5 milligrams and Metformin Hydrochloride at a strength of 500 milligrams per tablet. In addition to these active components, the formulation includes standard inactive excipients such as binding agents, fillers, and film-coating materials, which support the tablet’s physical integrity, appearance, and consistent behavior after ingestion. These excipients do not contribute to the therapeutic effect but are necessary for proper tablet formulation and stability.

Dosage Form

Diajard-M is available as an oral film-coated tablet. Each pack contains 14 tablets, providing a convenient supply for patients following a regular combination treatment schedule as directed by their physician. Being an oral solid dosage form, it can be swallowed directly with water without requiring special preparation.

Uses

Diajard-M 12.5/500mg is used to help improve blood sugar control in adults with type 2 diabetes mellitus, particularly in cases where treatment with a single medicine has not achieved adequate control, or where a physician determines that combination therapy is appropriate from the outset. It is typically used alongside dietary changes and regular physical activity as part of an overall diabetes management plan. This medicine is not intended for individuals with type 1 diabetes or for the management of diabetic ketoacidosis. The suitability of this combination for any individual patient should always be assessed by a qualified healthcare provider.

How to Use

Diajard-M should be taken exactly as prescribed by a physician, usually with meals to help reduce the likelihood of stomach-related discomfort associated with the Metformin component. The tablet should be swallowed whole with a glass of water and should not be crushed or chewed. Consistency in timing is generally encouraged to help maintain steady blood sugar control throughout the day. Patients should continue following any dietary or lifestyle guidance given by their doctor and must not adjust the dosage independently. Regular monitoring of blood sugar levels and kidney function is often recommended while using this combination medicine.

Side Effects

Diajard-M may cause side effects in some individuals, though not everyone experiences them. Commonly reported effects include gastrointestinal discomfort such as nausea, diarrhea, or stomach upset, particularly during the initial period of use, along with effects associated with the Empagliflozin component such as urinary tract infections, genital yeast infections, and increased urination. Some patients may also experience mild dizziness or symptoms related to dehydration. A rare but serious risk associated with Metformin-containing medicines is lactic acidosis, which can present as unusual muscle pain, difficulty breathing, stomach discomfort, or extreme tiredness, and requires immediate medical attention if suspected. Patients with kidney or liver concerns, a history of heavy alcohol use, or those undergoing procedures involving contrast dye should inform their doctor before using this medicine.

Pregnancy & Breastfeeding

The use of Diajard-M during pregnancy or breastfeeding should only take place under the specific direction of a qualified healthcare provider, as its suitability in these situations depends on individual clinical circumstances. Women who are pregnant, planning pregnancy, or breastfeeding should discuss their situation with their doctor before starting or continuing this combination medicine.

Storage Instructions

Diajard-M tablets should be stored in a cool, dry place away from direct sunlight and moisture, at the room temperature indicated on the packaging. Tablets should remain in their original blister pack until use to help protect them from humidity and light exposure. Keep out of reach of children and pets, and avoid storing in areas prone to temperature changes, such as bathrooms or vehicles.

FAQS

Q: Why does Diajard-M combine two medicines in one tablet?
Combining Empagliflozin and Metformin allows two different mechanisms to work together, which can offer more comprehensive blood sugar support and improve treatment convenience.

Q: Should Diajard-M be taken with food?
Yes, taking it with meals is generally recommended to help minimize stomach-related side effects linked to the Metformin component.

Q: Can Diajard-M replace insulin therapy?
No, it works differently from insulin and is not a substitute for insulin therapy in patients who require it.

Q: What should I do if I miss a dose of Diajard-M?
A missed dose should be taken as soon as remembered unless it is close to the next scheduled dose, in which case the missed dose should be skipped rather than doubled, as advised by a doctor.

Disclaimer

Always use this medicine strictly according to your doctor’s instructions and prescribed dosage.